The primary objective of this proposal is to secure funding to help support clinical cancer research at Vanderbilt University. From October, 1977 until June, 1986, clinical research was partly supported by funds obtained through the Southeastern Cancer Study Group. With the disbanding of the SECSG, Vanderbilt investigators sought and obtained membership in the Eastern Cooperative Oncology Group. Membership in ECOG came at the end of a funding cycle and only limited """"""""start-up"""""""" funds have been made available to assist in this transition.
The specific aims of this proposal include: 1) to increase participation in group-wide phase II and phase III clinical trials, 2) to develop innovative treatment protocols for lung cancer, testicular cancer, lymphomas and other malignancies, 3) participation in and development of pharmacology studies to be used in conjunction with ongoing ECOG trials, 4) collaboration in ongoing group-wide bone marrow transplantation studies and development of new studies, 5) and to maintain the high quality of data management as previously established during our long association with SECSG. These goals will be obtained through the close cooperation of investigators from the divisions of medical oncology and hematology and the assistance of investigators from the departments of radiation oncology, surgery and pathology. Vanderbilt investigators are members of several disease- oriented committees and chair several pilot and group-wide studies. Our bone marrow transplantation service is ECOG approved. We have an outstanding clinical pharmacology program which is well established and is actively participating in ECOG activities. In summary, Vanderbilt investigators are poised to become major contributors to ECOG both in terms of patient accrual as well as the development of innovative treatment protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA049957-03
Application #
3558888
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1989-05-01
Project End
1994-04-30
Budget Start
1991-05-01
Budget End
1992-04-30
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Berlin, Jordan D; Feng, Yang; Catalano, Paul et al. (2018) An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). Oncology 94:39-46
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75
Wagner, Lynne I; Zhao, Fengmin; Hong, Fangxin et al. (2015) Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). J Clin Oncol 33:740-8
Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:
Kahl, Brad S; Hong, Fangxin; Williams, Michael E et al. (2014) Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol 32:3096-102
Ciombor, Kristen K; Feng, Yang; Benson 3rd, Al Bowen et al. (2014) Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs 32:1017-27
Hodi, F Stephen; Lee, Sandra; McDermott, David F et al. (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744-53

Showing the most recent 10 out of 78 publications